Bells, you don't let the vax side of the business go: you keep it. It's just that you would own AHZ1 and AHZ2, rather than AHZ, the conglomerate.
The market has enough trouble valuing a medtech or biotech company as it is, without having to wrestle with 5+ very different subsidiaries, all at different stages of development.
It's a very weird and unnatural mix... I don't even know how it happened! Maybe some long-termer could tell me.
Did one of the bosses from long back say, "I have always had this urge to cure cancer"... Or "I just met a really clever guy who reckons he can come up with a vaccine for Herpes. I think we should give him some of our latest cap raise".. or something equally weird!!!!
Or was it the other way around: "Let's buy cardiocel as a quick and easy way to profits to self-fund our biotech aspirations?"
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)